Paul L Berns

CIK 1202769 · See Remarks · last filed 2026-08-21

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$215.91M
Companies
13
Total Filings
101
Lifetime Open-Market Net
$21.97M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

KARD price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O NEUMORA THERAPEUTICS, INC.
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Related Filers
ARCH Venture Fund XIII, L.P. — 2 joint filings, latest 2026-03-09
ARCH Venture Partners XIII, L.P. — 2 joint filings, latest 2026-03-09
ARCH Venture Partners XIII, LLC — 2 joint filings, latest 2026-03-09
Kristina Burow — 2 joint filings, latest 2026-03-09
Keith Crandell — 2 joint filings, latest 2026-03-09
Steven Gillis — 2 joint filings, latest 2026-03-09
Robert Nelsen — 2 joint filings, latest 2026-03-09
Clinton Bybee — 1 joint filings, latest 2026-03-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NMRA See Remarks 7,528,282 $0.35 $2.63M -$57.9K 8 2026-08-21
KARD Director 15,062,741 $12.74 $191.90M $20.00M 2 2026-06-24
LYEL 10%+ Owner 1,426,528 $13.62 $19.44M $12.50M 1 2026-03-09
Metsera, Inc. (MTSR) Delisted Director 0 $70.50 $0 $14.22M 3 2025-11-13
Unity Biotechnology, Inc. (UBX) Delisted Director 326 $0.20 $65 $0 7 2024-06-21
EQRx, Inc. (EQRXW) Delisted Director 0 $0.05 $0 $0 4 2023-11-09
JAZZ Director 8,290 $234.93 $1.95M -$3.76M 23 2021-08-09
VYNE Therapeutics Inc. (MNLO) Delisted Director — — — $0 2 2019-08-08
Anacor Pharmaceuticals, Inc. (ANAC) Delisted President and CEO 0 $10.19 $0 -$16.52M 14 2016-06-24
XENOPORT INC (XNPT) Delisted Director 15,000 — — -$525.2K 10 2016-05-19
Cellectar Biosciences, Inc. (CLRB.Z) Delisted Director 117,371 — — $248.8K 1 2016-04-21
Cellectar Biosciences, Inc. (CLRB.W) Delisted Director — — — $0 2 2015-06-10
ALLOS THERAPEUTICS INC (ALTH) Delisted Chief Executive Officer 0 — — -$4.14M 22 2012-09-05

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
NMRA Direct 7,395,185 98.2% 2026-02-19
LULU TRUST OF 2024 FBO OB
See footnote
133,097 1.8% 2026-02-19
Total 7,528,282
KARD Direct 20,706 0.1% 2026-06-24
By ARCH Venture Fund XIII, L.P. 15,042,035 99.9% 2026-06-24
Total 15,062,741
LYEL ARCH Venture Fund IX, L.P.
See footnote
1,426,528 100.0% 2026-03-09
Total 1,426,528
MTSR Direct 0 — 2025-11-13
ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII")
See footnote
0 — 2025-11-13
Total 0

Recent Filings · Page 10 of 11

101 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2009-03-12 ALLOS THERAPEUTICS INC (ALTH) Delisted Disp (D) −34,235 -$224.0K EDGAR
2009-02-25 ALLOS THERAPEUTICS INC (ALTH) Delisted Grant (A) +46,667 $0 EDGAR
2008-06-17 XENOPORT INC (XNPT) Delisted Mixed — -$364.5K EDGAR
2008-05-09 XENOPORT INC (XNPT) Delisted Grant (A) — $0 EDGAR
2008-03-12 ALLOS THERAPEUTICS INC (ALTH) Delisted Sell (S) −34,400 -$185.1K EDGAR
2008-02-27 ALLOS THERAPEUTICS INC (ALTH) Delisted Grant (A) — $0 EDGAR
2008-01-03 ALLOS THERAPEUTICS INC (ALTH) Delisted Buy (P) +5,000 $19.5K EDGAR
2007-06-01 XENOPORT INC (XNPT) Delisted Grant (A) — $0 EDGAR
2007-03-14 ALLOS THERAPEUTICS INC (ALTH) Delisted Sell (S) −23,625 -$152.5K EDGAR
2007-02-20 ALLOS THERAPEUTICS INC (ALTH) Delisted Grant (A) — $0 EDGAR
Showing 91–100 of 101
Page 10 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).